Jeffrey Heslop, MD
Interventional Cardiology · Boise, IDNPI 1144544644
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.3%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Edwards Lifesciences at 55.2% of the total. Reporting peaked in 2024 at $9,107 and has fallen 88.7% since, to $1,025 in 2025. Among interventional cardiology clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $62.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$9K
- Boston Scientific$5K
- Abbott$2K
- Abiomed$270
- Novartis$120
- Amgen$101
- plus $299 from 11 others
Across 14 payments — averaging $2401.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$34K
What the payments were for
- Speaking & faculty fees$4,00023%
- Grants$1451%
- Travel & lodging$4,38525%
- Food & beverage$8,64350%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 64 | $9,495 |
| Boston Scientific | 149 | $4,854 |
| Abbott | 26 | $2,060 |
| Abiomed | 6 | $270 |
| Novartis | 8 | $120 |
| Amgen | 5 | $101 |
| Pfizer | 4 | $59 |
| Shockwave Medical, Inc | 4 | $59 |
| Penumbra, Inc. | 1 | $50 |
| Livanova USA, Inc. | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| AstraZeneca | 1 | $15 |
| Biotronik Inc. | 1 | $14 |
| Teleflex LLC | 1 | $14 |
| Medtronic | 1 | $13 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$1,767
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,131
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$299
- Edwards SAPIEN XT Transcatheter Heart Valve$273
- MitraClip System$164
- Impella$157
- PASCAL$150
- WATCHMAN FLX$148
- GENERAL - STRUCTURAL HEART$145
- MitraClip$127
- CentriMag$116
- AMPLATZER AMULET$110
- SAPIEN 3 Ultra RESILIA$103
How this compares
$17,199 in reported general payments places this provider in the 90th percentile of 29 interventional cardiology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $15,848 |
| Metoprolol Succinate | 33 | $272 |
| Ezetimibe | 14 | $241 |
| Atorvastatin Calcium | 21 | $213 |
| Potassium Chloride | 13 | $185 |
| Spironolactone | 21 | $174 |
| Furosemide | 18 | $146 |
| Losartan Potassium | 13 | $93 |
| Warfarin Sodium | 15 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $59 | $15,84811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 29 interventional cardiology providers in Idaho.
Other interventional cardiology in Boise
- Joseph WalshBoise$115K
- Kara DenbyBoise$18K
- Kendra CoonseBoise$17K
- Patrick ColemanBoise$11K
- Robert DuerrBoise$11K
- Frederick CostelloBoise$5K
- Alex JohnsonBoise$3K
- David CoyleBoise$3K
- Mark ParentBoise$2K
- Carl KapadiaBoise$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.